To the content
2 . 2020

Clinical efficacy of probiotic strains of the Bifidobacterium and Lactobacillus

Abstract

The article analyzes the effectiveness of the most studied probiotic strains that are used for prophylactic or therapeutic purposes. The requirements for probiotic microorganisms are described, depending on the form in which they are used. However, their scope most often covers both prevention and treatment of various functional disorders and diseases of the gastrointestinal tract. At the same time, a lot of data has been accumulated on the effectiveness of probiotics for the treatment and prevention of diseases of other organs and organism systems. Most strains are successfully used as dietary supplements, and some of them have found their application in food industry.

Keywords:probiotics, dietary supplements, probiotic strains, functional disorders, safety

Funding. The study had no sponsor support.

Conflict of interests. The authors declare no conflict of interests.

For citation: Drozdov V.N., Astapovskiy A.A., Serebrova S.Yu., Lazareva N.B., Shikh E.V. Clinical efficacy of probiotic strains of the Bifidobacterium and Lactobacillus. Voprosy pitaniia [Problems of Nutrition]. 2020; 89 (2): 107-15. DOI: 10.24411/0042-8833-2020-10021 (in Russian)

References

1. Lilly D., Stillwell R. Probiotics: growth-promoting factors produced by microorganisms. Science. 1965; 147 (3659): 747–8. DOI: 10.1126/science.147.3659.747.

2. Ventura M., Turroni F., Sinderen D. Bifidobacteria of the human gut: Our special friends. Diet-microbe interactions in the gut. Effects on human health and disease. 2015: 41–51. DOI: 10.1016/B978-0-12-407825-3.00004-6.

3. De Angelis M., Gobbetti M. Lactobacillus Spp.: general characteristics. In: Reference Module in Food Science. Elsevier, 2016. DOI: 10.1016/B978-0-08-100596-5.00851-9.

4. World Gastroenterology Organisation Global Guidelines. Probiotics and Prebiotics. February 2017. URL: https://www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-english

5. Degnan F.H. The US Food and Drug Administration and Probiotics: Regulatory Categorization. Clin Infect Dis. 2008; 46 (suppl 2): S133–6. DOI: 10.1086/523324.

6. Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014; 11 (8): 506–14. DOI: 10.1038/nrgastro.2014.66.

7. URL: http://pharmacopoeia.ru/gosudarstvennaya-farmakopeya-xiii-online-gf-13-online/

8. FAO/WHO. Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ontario, Canada, April 30 and May 1, 2002. URL: https://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf.

9. Fda.gov [Electronic resource]. Generally Recognized as Safe (GRAS). 2019. URL: https://www.fda.gov/food/food-ingredients-packaging/generally-recognized-safe-gras.

10. Yuan F., Ni H., Asche C.V., Kim M., Walayat S., Ren J. Efficacy of Bifidobacterium infantis 35 624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin. 2017; 33 (7): 1191–7. DOI: 10.1080/03007995.2017.1292230.

11. Lee B.J., Bak Y.T. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil. 2011; 17 (3): 252–66. DOI: 10.5056/jnm.2011.17.3.252.

12. Martínez-Martínez M.I., Calabuig-Tolsá R., Cauli O. The effect of probiotics as a treatment for constipation in elderly people: a systematic review. Arch Gerontol Geriatr. 2017; 71: 142–9. DOI: 10.1016/j.archger.2017.04.004.

13. Pagnini C., Corleto V.D., Martorelli M., Lanini C., D’Ambra G., Di Giulio E., et al. Mucosal adhesion and anti-inflammatory effects of Lactobacillus rhamnosus GG in the human colonic mucosa: a proof-of-concept study. World J Gastroenterol. 2018; 24 (41): 4652–62. DOI: 10.3748/wjg.v24.i41.4652.

14. Tong J., Ra Z., She J., Zhan C., Xiao S. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007; 25 (2): 155–68. DOI: 10.1111/j.1365-2036.2006.03179.x.

15. Fang H.R., Zhang G.Q., Cheng J.Y., Li Z.Y. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials. Eur J Pediatr. 2019; 178 (1): 7–16. DOI: 10.1007/s00431-018-3282-z.

16. Kotzampassi K., Stavrou G., Damoraki G., Georgitsi M., Basdanis G., Tsaousi G., et al. A four-probiotics regimen reduces postoperative complications after colorectal surgery: a randomized, double-blind, placebo-controlled study. World J Surg. 2015; 39: 2776–83. DOI: 10.1007/s00268-015-3071-z.

17. Anukam K., Osazuwa E., Ahonkhai I., Ngwu M., Osemene G., Bruce A.W., et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect. 2006; 8: 1450–4. DOI: 10.1016/j.micinf.2006.01.003.

18. Homayouni A., Bastani P., Ziyadi S., Mohammad-Alizadeh-Charandabi S., Ghalibaf M., Mortazavian A.M., et al. Effects of probiotics on the recurrence of bacterial vaginosis: a review. J Low Genit Tract Dis. 2014; 18 (1): 79–86. DOI: 10.1097/LGT.0b013e31829156ec.

19. Tarasova L.A., Danilova V.N., Voronina L.N. Experience in the correction of the intestine microbiotadys dysbalance on the background of secondary lactase deficiency. Pediatricheskaya farmakologiya [Pediatric Pharmacology]. 2011; 8 (4): 122–4. (in Russian)

20. Drossman D.A., Camilleri M., Mayer E.A., Whitehead W.E. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002; 123: 2108–31. DOI: 10.1053/gast.2002.37095.

21. Spiller R., Aziz Q., Creed F., Emmanuel A., Houghton L., Hungin P., et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007; 56 (12): 1770–98. DOI: 10.1136/gut.2007.119446.

22. Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm. 2004; 10 (4): 299–309. DOI: 10.18553/jmcp.2004.10.4.299.

23. Carroll I.M., Ringel-Kulka T., Keku T.O., Chang Y.H., Packey C.D., Sartor R.B., et al. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2011; 301: G799–807. DOI: 10.1152/ajpgi.00154.2011.

24. Carroll I.M., Ringel-Kulka T., Siddle J.P., Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2012; 24 (6): 521–30.e248. DOI: 10.1111/j.1365-2982.2012.01891.x.

25. Whorwell P.J., Altringer L., Morel J., Bond Y., Charbonneau D., O’Mahony L., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35 624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006; 101: 1581–90. DOI: 10.1111/j.1572-0241.2006.00734.x.

26. Suares N., Ford A. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106 (9): 1582–91; quiz P. 1581, 1592. DOI: 10.1038/ajg.2011.164.

27. Dennison C., Prasad M., Lloyd A., Bhattacharyya S.K., Dhawan R., Coyne K. The health-related quality of life and economic burden of constipation. PharmacoEconomics. 2005; 23 (5): 461–76. DOI: 10.2165/00019053-200523050-00006.

28. Sanchez M.I., Bercik P. Epidemiology and burden of chronic constipation. Can J Gastroenterol. 2011; 25 (suppl B): 11B–5B. DOI: 10.1155/2011/974573.

29. Hooi J.K.Y., Lai W.Y., Ng W.K., Suen M.M.Y., Underwood F.E., Tanyingoh D., et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017; 153 (2): 420–9. DOI: 10.1053/j.gastro.2017.04.022.

30. De Francesco V., Giorgio F., Hassan C., Manes G., Vannella L., Panella C., et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointest Liver Dis. 2010; 19 (4): 409–14.

31. Pimanov S.I., Makarenko E.V. Maastricht V/Florentine consensus recommendations for the treatment of Helicobacter pylori infection. Consilium Medicum. 2017; (8.1): 8–27. (in Russian)

32. Mehrabani S. Helicobacter pylori infection in children: a comprehensive review. Maedica (Buchar). 2019; 14 (3): 292–7. DOI: 10.26574/maedica.2019.14.3.292.

33. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68 (6): 394–424. DOI: 10.3322/caac.21492.

34. Peterson C.T., Sharma V., Elmén L., Peterson S.N. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin Exp Immunol. 2014; 179 (3): 363–77. DOI: 10.1111/ cei.12474

35. Muszer M., Noszczyńska M., Kasperkiewicz K., et al. Human microbiome: when a friend becomes an enemy. Arch Immunol Ther Exp. 2015; 63 (4): 287–98. DOI: 10.1007/s00005-015-0332-3.

36. Kasai C., Sugimoto K., Moritani I., Tanaka J., Oya Y., Inoue H., et al. Comparison of human gut microbiota in control subjects and patients with colorectal carcinoma in adenoma: terminal restriction fragment length polymorphism and next-generation sequencing analyses. Oncol Rep. 2016; 35: 325–33. DOI: 10.3892/or.2015.4398.

37. Prilepskaya V.N, Kira E.F., et al. Clinical recommendations for the diagnosis and treatment of diseases accompanied by pathological secretions from the female genital tract. 2nd ed. correct. and suppl. In: Members of the expert Council of the Russian society of obstetricians and gynecologists. Moscow, 2019. ISBN-978-5-89084-052-3. (in Russian)

38. Fuller R. Probiotic foods. Current use and future developments. Int Food Ingred. 1993; 3: 23–6.

39. Jungersen M., Wind A., Johansen E., Christensen J.E., Stuer-Lauridsen B., Eskesen D. The science behind the probiotic strain Bifidobacterium animalis subsp. lactis BB-12®. Microorganisms. 2014; 2: 92–110. DOI: 10.3390/microorganisms2020092.

40. Zimnyakov V.M., Gavryushina I.V. Impact on technological properties of prebiotics dairy and meat products. Innovatsionnaya tekhnika i tekhnologiya [Innovative Equipment and Technology]. 2014; (4): 8–12. (in Russian)

41. Silva M., Jacobus N.V., Deneke C., Gorbach S.L. Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother. 1987; 31 (8): 1231–3. DOI: 10.1128/aac.31.8.1231.

42. Gorbach S.L., Goldin B.R. Lactobacillus strains and methods of selection. US Patent. N 4839281.

43. Doron S., Snydman D.R., Gorbach S.L. Lactobacillus GG: bacteriology and clinical applications. Gastroenterol Clin North Am. 2005; 34 (3): 483–98, ix. DOI: 10.1016/j.gtc.2005.05.011.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

SCImago Journal & Country Rank
Scopus CiteScore
CHIEF EDITOR
CHIEF EDITOR
Viktor A. Tutelyan
Full Member of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, Scientific Director of the Federal Research Centre of Nutrition, Biotechnology and Food Safety (Moscow, Russia)

Journals of «GEOTAR-Media»